Market Overview: The S&P 500 has risen 16% year-to-date, driven by Big Tech's advancements in AI and digital infrastructure, while opportunities also exist in the penny-stock sector for potential high returns.
Acrivon Therapeutics: Acrivon is a clinical-stage biotech focused on precision oncology, with promising drug candidates ACR-368 and ACR-2316 showing potential for significant market upside, supported by positive analyst ratings and upcoming clinical data.
VistaGen: VistaGen is developing innovative treatments for central nervous system disorders, particularly social anxiety disorder, with its lead candidate fasedienol nearing key trial milestones, and analysts expressing confidence in its potential success.
Analyst Insights: Both Acrivon and VistaGen have received strong buy ratings from analysts, highlighting their promising pipelines and potential for substantial stock price increases, with Acrivon projected to rise by 553% and VistaGen by 205% over the next year.
ACRV
$2.5+Infinity%1D
Analyst Views on ACRV
Wall Street analysts forecast ACRV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRV is 10.60 USD with a low forecast of 6.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast ACRV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRV is 10.60 USD with a low forecast of 6.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.530
Low
6.00
Averages
10.60
High
19.00
Current: 2.530
Low
6.00
Averages
10.60
High
19.00
Oppenheimer
Oppenheimer
Outperform
downgrade
$9 -> $8
2025-08-14
Reason
Oppenheimer
Oppenheimer
Price Target
$9 -> $8
2025-08-14
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on Acrivon Therapeutics to $8 from $9 and keeps an Outperform rating on the shares following Q2 results. The firm notes Phase 1 trial of ACR-2316 is on track for the second half of 2025.
JonesResearch
Buy
to
Hold
downgrade
2025-05-16
Reason
JonesResearch
Price Target
2025-05-16
downgrade
Buy
to
Hold
Reason
Oppenheimer
Oppenheimer
Outperform
downgrade
$10 -> $9
2025-05-14
Reason
Oppenheimer
Oppenheimer
Price Target
$10 -> $9
2025-05-14
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on Acrivon Therapeutics to $9 from $10 and keeps an Outperform rating on the shares. The firm is adjusting its model after the company's Q1 results and updates on its cash and share position, the analyst tells investors in a research note.
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$19
2025-03-28
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$19
2025-03-28
Reiterates
Strong Buy
Reason
About ACRV
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
